{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5575","upperLimit":"0.6934","value":"0.6255"},{"groupId":"OG001","lowerLimit":"0.5178","upperLimit":"0.6569","value":"0.5874"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"226"}],"units":"Participants"}],"description":"Probability of no relapse, secondary malignancy, or death after 4 year in the study","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.\n\nDactinomycin: Given IV Cyclophosphamide: Given IV Vincristine Sulfate: Given IV Radiation Therapy: Undergo radiotherapy Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies","id":"OG000","title":"Vincristine, Dactinomycin, Cyclophosphamide (VAC)"},{"description":"Patients receive VAC chemotherapy alternating with VI chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13,16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 13, 22, 28, 34, and 40; cyclophosphamide IV over 1 hour on day 1 of weeks 1,10, 13, 22, 28, 34, and 40; and irinotecan hydrochloride IV over 1 hour on days 1-5 of weeks 4, 7, 16, 19, 25, 31, and 37. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.","id":"OG001","title":"VAC Alternating With Vincristine, Irinotecan (VI)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"4 years","title":"Event Free Survival (EFS)","type":"PRIMARY","unitOfMeasure":"Probability"}